Ingenia Therapeutics, a clinical-stage biotechnology company, announced that its shares have begun trading on the KOSDAQ market. The initial public offering marks a strategic step for the Boston-based firm as it seeks to accelerate the global commercialization of its next-generation vascular-targeted therapies.

Founded in 2018, Ingenia leverages technologies originating from the Korea Advanced Institute of Science and Technology (KAIST) and the Institute for Basic Science (IBS). The company’s platform relies on two core technologies: TIE-body, which activates the TIE2 receptor, and LCIDEC, designed to stabilize damaged vasculature while removing disease-causing proteins.

Late-Stage Retina Program

The company’s most advanced asset is IGT-427 (MK-8748), an investigational bispecific antibody acting as a TIE2 agonist and VEGF inhibitor. It is currently in late-stage clinical trials for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).

In 2022, Ingenia entered a research collaboration and licensing agreement with EyeBio. EyeBio was subsequently acquired in 2024 and became a wholly owned subsidiary of Merck (known as MSD outside the US and Canada).

Pipeline Diversification

Ingenia plans to use IPO proceeds to expedite clinical development across its broader pipeline:

• IGT-303 (Chronic Kidney Disease): Currently in Phase 2a trials across Australia, New Zealand, and South Korea, with global out-licensing targeted for 2027.
• IGT-532 (Solid Tumors): Advancing toward clinical trials as a novel oncology therapy intended to offer superior efficacy compared to conventional VEGF/PD-1 bispecific antibodies.
• Preclinical Assets: Candidates for glaucoma (IGT-302) and pulmonary arterial hypertension (IGT-627) are being advanced through partnerships with Harvard Medical School and Emory University School of Medicine.

What the Numbers Show

The capital raise underscores a shift from pure R&D dependency to market-funded execution. With no disclosed revenue figures or cash balances in the filing, the company’s immediate financial imperative is clear: convert equity value into clinical milestones. The timeline for IGT-303 out-licensing in 2027 sets a near-term horizon for potential non-dilutive funding or partnership revenue, balancing the burn rate associated with multi-regional Phase 2a trials.

Sangyeul Han, PhD, CEO of Ingenia Therapeutics, stated that going public is a transformative milestone. He emphasized the company’s commitment to demonstrating technological excellence and executing key clinical milestones to drive sustainable shareholder value.